Therapy with clopidogrel or rivaroxaban has equivalent impacts on recurrence of thromboembolism and survival in cats following cardiogenic thromboembolism: the SUPERCAT study

被引：0

作者：

Brainard, Benjamin M. ^{[1
]}

Coleman, Amanda E. ^{[1
]}

Kurosawa, Anne ^{[2
]}

Rush, John E. ^{[3
]}

Hogan, Daniel F. ^{[4
]}

Brooks, Marjory B. ^{[5
]}

Kraus, Marc S. ^{[6
]}

机构：

[1] Univ Georgia, Coll Vet Med, Dept Small Anim Med & Surg, Athens, GA 30602 USA

[2] Univ London, Royal Vet Coll, London, England

[3] Tufts Univ, Cummings Sch Vet Med, Dept Clin Sci, North Grafton, MA USA

[4] Purdue Univ, Coll Vet Med, Dept Vet Clin Sci, W Lafayette, IN USA

[5] Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Ithaca, NY USA

[6] Univ Penn, Sch Vet Med, Dept Clin Sci & Adv Med, Philadelphia, PA USA

来源：

JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION | 2025年 / 263卷 / 04期

关键词：

rivaroxaban; thromboembolism; clopidogrel; feline; coagulation; FACTOR-XA INHIBITOR; ARTERIAL THROMBOEMBOLISM; DOUBLE-BLIND; PHARMACODYNAMICS; PHARMACOKINETICS; BAY-59-7939; WEIGHT; CARDIOMYOPATHY; PREVENTION; ASPIRIN;

D O I：

10.2460/javma.24.09.0584

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

OBJECTIVE To assess the impact of clopidogrel or rivaroxaban administration on recurrence of arterial thromboembolism (ATE) in cats that have recovered from cardiogenic ATE. METHODS This multicenter prospective double-masked protocol enrolled 45 cats that had recovered from cardiogenic ATE and were randomized to receive either clopidogrel (18.75 mg/cat, PO; n = 19) or rivaroxaban (2.5 mg/cat, PO; 26) as sole anticoagulant therapy for up to 2 years after the initial ATE. Primary outcome measures included recurrent ATE or death from any cause. In addition to bimonthly internet-based surveys of animal quality of life, echocardiograms were performed by veterinary cardiologists at 2, 6, 12, and 18 months after initial ATE. RESULTS 17 cats experienced ATE recurrence: 7 of 19 (37%) in the clopidogrel group and 10 of 26 (39%) in the rivaroxaban group. Three cats in each group survived for the entire 2-year study without recurrence. In the clopidogrel group, median (95% CI) time to ATE recurrence was 663 days (150 to not calculable) and in the rivaroxaban group, 513 days (242 to not calculable). Median time from enrollment to death from cardiac or noncardiac causes was also not dif- ferent between treatment groups. CONCLUSIONS Single-agent antithrombotic therapy with rivaroxaban in cats recovered from cardiogenic embolism delayed recur- rence of ATE for a similar time period as single-agent therapy with clopidogrel. CLINICAL RELEVANCE In cats that have recovered from cardiogenic ATE, either rivaroxaban or clopidogrel may be used for single-agent thromboprophylaxis to delay ATE recurrence.

引用

页数：10